Objectif As we get older, we all will develop eyesight problems. Around the age of 65 more than half of us suffer from eye lens clouding, or cataracts. Cataract surgery is now the most common operation in Europe, with 4.3 million people getting treated each year, a figure that will only increase due to our fast aging population. However, 200,000 of them are not satisfied with the outcome of their eye correcting surgeries as they can’t experience on forehand what their vision will be. Voptica has developed the Visual Adaptive Optics (VAO) simulator, a disruptive innovation in eye testing, allowing patients to experience the effect of intraocular lenses or laser surgery on their vision before the actual operation, helping the patient and doctor to select their best solution and understand what their vision will be like post-surgery.Our technology is used by world-leading research institutes and lens-manufactures, but to prepare VAO for clinical market introduction our project BeVision will refine its software protocols, make it interoperable and clinically validate the technology.After a successful clinical validation, VAO will be the only medical device in the world that can measure objectively all eye aberrations of patients and, subsequently, simulate the different optical solutions to correct the patient’s eye imperfections during visual testing. Our technology will dramatically improve the outcomes of cataract and laser refractive surgeries. Our highly competitive technology can swiftly disrupt the $4.4 billion ophthalmology device market, generating a rapid business growth for Voptica, with a cumulative revenue of € 36.4m and a profit of € 8.6m by 2025. To make BeVision a commercial success, we have assembled a consortium with a solid track record in the development, optimisation, clinical validation and commercialisation of ophthalmic devices and have all the skills and resources for its commercial exploitation to benefit our business and Europe. Champ scientifique medical and health sciencesclinical medicinesurgerysocial scienceseconomics and businessbusiness and managementbusiness modelsmedical and health sciencesclinical medicineophthalmologyengineering and technologymaterials engineeringnatural sciencesphysical sciencesopticslaser physics Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.4. - Active ageing and self-management of health H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument H2020-EU.3.1.6. - Health care provision and integrated care Thème(s) SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-2-2016-2017 Régime de financement SME-2 - SME instrument phase 2 Coordinateur VOPTICA S.L. Contribution nette de l'UE € 1 740 751,77 Adresse CAMPUS DE ESPINARDO, CTRA. MADRID KM.388, PARQUE CIENTIFICO DE MURCIA. EDIFICIO T. LOCALES T1/3 Y T2/9 30100 Murcia Espagne Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Sur Región de Murcia Murcia Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 2 486 788,25
